Neurocrine Biosciences Retained Earnings increased by 31.7% to $589.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 11224.5%, from -$5.30M to $589.60M. Over 5 years (FY 2020 to FY 2025), Retained Earnings shows an upward trend with a -9.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase signals strong historical profitability and reinvestment, while a decrease may indicate losses or significant dividend payouts.
This represents the cumulative net income earned by the company since its inception, minus any dividends paid to shareho...
A key metric for all established companies; growth rates are compared against peers to gauge long-term success.
retained_earnings| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$651.00M | -$628.50M | -$635.80M | -$547.40M | -$564.30M | -$495.80M | -$406.80M | -$483.40M | -$387.90M | -$304.80M | -$157.10M | -$113.70M | -$48.70M | $81.10M | $29.20M | -$5.30M | $84.50M | $294.00M | $447.70M | $589.60M |
| QoQ Change | — | +3.5% | -1.2% | +13.9% | -3.1% | +12.1% | +18.0% | -18.8% | +19.8% | +21.4% | +48.5% | +27.6% | +57.2% | +266.5% | -64.0% | -118.2% | >999% | +247.9% | +52.3% | +31.7% |
| YoY Change | — | — | — | — | +13.3% | +21.1% | +36.0% | +11.7% | +31.3% | +38.5% | +61.4% | +76.5% | +87.4% | +126.6% | +118.6% | +95.3% | +273.5% | +262.5% | >999% | >999% |